Oligomerix to Present at Alzheimer’s Association International Conference

Oligomerix to Present at Alzheimer’s Association International Conference




Oligomerix to Present at Alzheimer’s Association International Conference

— Presentation will be held on Thursday, July 29 —

WHITE PLAINS, N.Y.–(BUSINESS WIRE)–Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced that the Company will be presenting preclinical data on its oral, tau self-association small molecule inhibitor lead program, OLX-07010, at the 2021 Alzheimer’s Association International Conference (AAIC), which will be held from July 26-30 in Denver and online. Oligomerix plans to complete preclinical testing of OLX-07010 by year end and begin Phase 1 clinical trials by 2Q22.

Additional details for the AAIC presentation can be found below:

Presentation Title: In vivo validation of therapeutic efficacy of a small molecule lead targeting tau self-association in JNPL3 mice

Session Date and Time: Thursday, July 29, 1:00pm to 2:15pm MT

Session Name: Nonhuman: A potpourri of preclinical diagnostic and therapeutic studies

Registration: https://www.alz.org/aaic/

About Oligomerix’s Lead Program

Oligomerix’s lead candidate is an oral, small molecule inhibitor of tau self-association that targets the beginning of the tau aggregation cascade, a process thought to be important in the development of Alzheimer’s disease and other neurodegenerative disorders. Our lead compound, OLX-07010, has demonstrated efficacy in several animal models of neurodegeneration and, upon completion of its preclinical program in the next couple of months, will start Phase 1 clinical studies in early 2022.

About Oligomerix, Inc.

Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease.

With a focus on oral, small molecule, tau self-association inhibitors, Oligomerix seeks to develop therapies for Alzheimer’s disease and other dementias that are easy to administer and cost effective, and which are expected to significantly add to newly emerging high-cost therapeutic options such as the monoclonal antibody targeted against beta-amyloid that was recently approved by the U.S. FDA.

Oligomerix is headquartered at the Westchester Park Center in White Plains, New York and has lab facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine. Follow Oligomerix on Twitter and LinkedIn.

Oligomerix is seeking strategic partners to support the acceleration and advancement of these important programs. For more information about Oligomerix, please visit our new website at https://oligomerix.com/.

Contacts

Company Contacts
Jack Pasini

Chief Commercial Officer

917-912-4088

jpasini@oligomerix.com

James Moe, Ph.D., MBA

President and CEO

212-568-0365 Ext. 104

jmoe@oligomerix.com

Media Contacts
Michelle Linn

Bioscribe

774-696-3803

michelle@bioscribe.com